Citi analyst Yigal Nochomovitz upgraded Crispr Therapeutics to Buy from Neutral.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on CRSP:
- Crispr Therapeutics price target lowered to $110 from $123 at Chardan
- Crispr Therapeutics reports Q2 EPS (98c), consensus ($2.12)
- CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2023 Financial Results
- CRSP Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Crispr Therapeutics call volume above normal and directionally bullish